In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 101 to 125 of 301

TitleTypeExpected publication date
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]Technology appraisal guidanceTBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]Technology appraisal guidanceTBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]Technology appraisal guidanceTBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidance
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Technology appraisal guidanceTBC
Ianalumab for treating active Sjogren's syndrome ID6634Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]Technology appraisal guidanceTBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]Technology appraisal guidanceTBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]Technology appraisal guidanceTBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]Technology appraisal guidanceTBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Technology appraisal guidance
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Technology appraisal guidanceTBC
Insulin efsitora alfa for treating type 2 diabetes [ID6499]Technology appraisal guidance
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Technology appraisal guidance
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]Technology appraisal guidanceTBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]Technology appraisal guidanceTBC
Iptacopan for treating primary IgA nephropathy [ID6640]Technology appraisal guidanceTBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All